Calycosin down-regulates c-Met to suppress development of glioblastomas

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Glioblastomas are aggressive brain tumors with limited treatment options.
• The precise molecular targets of the natural compound calycosin in glioblastoma remain largely unknown.
• Identifying novel therapeutic targets is crucial for developing effective glioblastoma treatments.

Purpose of the Study:

• To investigate c-Met as a potential molecular target of calycosin in suppressing glioblastomas.
• To elucidate the mechanisms by which calycosin exerts its anti-tumor effects in glioblastoma cells.

Main Methods:

• Cell proliferation, invasion, and apoptosis assays were performed on calycosin-treated U251 and U87 glioblastoma cells.
• mRNA expression levels of Dtk, c-Met, Lyn, and PYK2 were analyzed.
• Western blot assays were used to assess protein expression and phosphorylation levels of c-Met, MMP9, and AKT.
• Experiments involved c-Met overexpression and the use of an AKT inhibitor (LY294002).

Main Results:

• Calycosin treatment suppressed cell proliferation and invasion while inducing apoptosis in U87 and U251 cells.
• Calycosin significantly down-regulated c-Met, matrix metalloproteinases-9 (MMP9), and phosphorylated AKT (p-AKT) expression.
• Overexpression of c-Met enhanced MMP9 and p-AKT levels and increased cell invasion, effects that were reversed by calycosin.
• An AKT inhibitor affected MMP9 and p-AKT but not c-Met expression.

Conclusions:

• Calycosin demonstrates anti-glioblastoma activity by targeting the c-Met signaling pathway.
• The anti-tumor effects of calycosin appear to be mediated through the modulation of MMP9 and AKT signaling.
• These findings suggest calycosin as a potential therapeutic agent for glioblastoma treatment targeting c-Met.